COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,755 Articles (22,502 medRxiv, 8,253 bioRxiv)

Most recent first Previous |  Page 1183: Articles 11821-11830  | Next

A method to reduce ELISA serial dilution assay workload applied to SARS-CoV-2 and seasonal HCoVs
Pattinson, D., Jester, P., Guan, L., Yamayoshi, S., Chiba, S., Presler, R., Rao, H., Iwatsuki-Horimoto, K., Hagihara, M., Ikeda, N., Uchida, T., Mitamura, K., Halfmann, P., Neumann, G., Kawaoka, Y.
10.1101/2021.09.13.21263523 — Posted: 2021-09-21
COVID-19 epidemics monitored through the logarithmic growth rate and SIR model
Konishi, T.
10.1101/2021.09.13.21263483 — Posted: 2021-09-21
Characteristics and outcomes of an international cohort of 400,000 hospitalised patients with Covid-19
ISARIC Clinical Characterisation Group, , Kartsonaki, C.
10.1101/2021.09.11.21263419 — Posted: 2021-09-21
An Analysis of SARS-CoV-2 Vaccine Breakthrough Infections and Associated Clinical Outcomes
Kerwin, H., Briggs, R., Nair-Desai, S., Gorzalski, A., Pandori, M., Friedhoff, S., Tsai, T.
10.1101/2021.09.09.21262448 — Posted: 2021-09-21 Discussion: Onsite
Equivalency of Protection from Natural Immunity in COVID-19 Recovered Versus Fully Vaccinated Persons: A Systematic Review and Pooled Analysis
Shenai, M. B., Rahme, R., Noorchasm, H.
10.1101/2021.09.12.21263461 — Posted: 2021-09-21
Absence of Excess Mortality in a Highly Vaccinated Population During the Initial Covid-19 Delta Period.
Faust, J. S., Du, C., Mayes, K. D., Renton, B., Li, S.-X., Lin, Z., Krumholz, H.
10.1101/2021.09.16.21263477 — Posted: 2021-09-21
Decreased door-to-balloon time in patients with ST-segment elevation myocardial infarction during the early COVID-19 pandemic in South Korea - an observational study
Ryu, S., Kim, D., Jung, L. Y., Kim, B., Lee, C.-S.
10.1101/2021.09.17.21263760 — Posted: 2021-09-21
Estimates of presumed population immunity to SARS-CoV-2 by state in the United States, August 2021
Stoner, M. C. D., Angulo, F. J., Rhea, S., Brown, L. M., Atwell, J. E., Nguyen, J. L., McLaughlin, J., Swerdlow, D. L., MacDonald, P. D. M.
10.1101/2021.09.17.21263759 — Posted: 2021-09-21
Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a sixteen-week interval between doses
Tauzin, A., Gong, S. Y., Beaudoin-Bussieres, G., Vezina, D., Gasser, R., Nault, L., Marchitto, L., Benlarbi, M., Chatterjee, D., Nayrac, M., Laumaea, A., Prevost, J., Boutin, M., Sannier, G., Nicolas, A., Bourassa, C., Gendron-Lepage, G., Medjahed, H., Goyette, G., Bo, Y., Perreault, J., Gokool, L., Morrisseau, C., Arlotto, P., Bazin, R., Dube, M., De Serres, G., Brousseau, N., Richard, J., Rovito, R., Cote, M., Tremblay, C., Marchetti, G. C., Duerr, R., Martel-Laferriere, V., Kaufmann, D. E., Finzi, A.
10.1101/2021.09.17.21263532 — Posted: 2021-09-21
Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2.
Ukey, R., Bruiners, N., Mishra, H., Mishra, P. K., McCluskey, D., Onyuka, A., Chen, F., Pinter, A., Weiskopf, D., Sette, A., Roy, J., Gaur, S., Gennaro, M. L.
10.1101/2021.09.17.21263528 — Posted: 2021-09-21

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).